Kelly, the winner of our first Golden Ticket contest has had an incredible journey, See how she's transformed her look–all with her wonderful husband Lattie by her side!
Are you an entrepreneur or innovator? Your new approaches or new applications of an everyday idea can advance the healthiest generation possible — “GenH” — by supporting those on the front lines of care.
The American Academy of Dermatology’s new SkinSerious campaign is raising awareness about skin disease and the specialty. The Skin Serious initiative kicked off at the AAD Annual Meeting in Orlando this month. New research presented at this year’s meeting focused on skin disease prevention and treatment. Galderma and Moderning Medicine are teaming up for a new integrated OTC ecommerce platform designed by Modernizing Medicine to make it easier for healthcare providers to create materials about patient treatment regimens and provide product recommendations to patients. Pershing Square Capital Management—for which Bill Ackman is CEO—has sold its investment in Valeant Pharmaceuticals International.
This webcast will examine an innovative research project funded by the National Psoriasis Foundation (NPF). Pranab Mukherjee, Ph.D., of Case Western Reserve University, received NPF’s Lozick Discovery Research Grant to study the role of the skin microbiome and mycobiome in the development of psoriasis. The microbiome (microorganisms) and mycobiome (fungi) on the skin are believed to impact the development of psoriasis lesions.
Another record year for Bayer. See Werner Baumann’s video statement on fiscal 2016 here. Get more facts: www.annualreport2016.bayer.com
There may soon be a new gold standard in acne therapy – gold nanoparticles. Evidence is mounting that the combination of a laser and a topical suspension of gold- or silver-coated silica nanoparticles can ablate the inner lining of the pilosebaceous unit, dramatically reducing or eliminating acne
“Consider the effects of the mind on the skin when treating patients with some skin diseases.” That was the message of several speakers during a session titled “The Skin and the Mind” at the annual meeting of the American Academy of Dermatology. “I certainly believe that the time has come to use stress alleviation techniques, at least for selected patients, and this should certainly be part of our armamentarium in the clinic,” said Richard D. Granstein, MD, George W. Hambrick Jr. professor and chairman of the department of dermatology, Cornell University, New York.
Janus kinase inhibitors are “currently the most promising treatments” for alopecia areata, but they are expensive, are not approved for this indication, and so getting insurance coverage for these treatments can be difficult, Carolyn Goh, MD, said at the annual meeting of the American Academy of Dermatology.
Pregnancy prevention remains a challenge when prescribing isotretinoin to women of childbearing years with acne, Megha M. Tollefson, MD, said at the annual meeting of the American Academy of Dermatology.
Two hair loss clinical grading tools can help physicians and their female androgenetic alopecia patients set medical treatment expectations, and make tracking progress both easier and more accurate, according to the dermatologist who developed the scales.
In the past few years, there have been “exciting” advances in noninvasive techniques to permanently remove fat, according to Suzanne Kilmer, MD, of the department of dermatology, University of California, Davis. There are devices now available to reduce fat “in a permanent way that’s not injurious, it’s not uncomfortable – patients love it,”
A study that used patient-reported outcomes to assess the impact of different contraceptive methods on acne provided “fascinating results,” Lawrence F. Eichenfield, MD, said at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation. “Progestins are present in birth control for the birth control, but they’re not usually good for the acne,”
In an interview, pediatric dermatologist Lawrence F. Eichenfield, MD, discusses a recently approved topical therapy for atopic dermatitis, which provides a nonsteroidal option for treating the disease in young patients. The product, crisaborole (Eucrisa), is a phosphodiesterase 4 (PDE-4) inhibitor, a new type of chemical entity “based on a different pathway of decreasing inflammation,” said Dr. Eichenfield
Two hyaluronic acid products now available in the United States are “much more stretchable and flexible” than other fillers, according to Nowell Solish, MD, of the University of Toronto. The dermal fillers, Restylane Defyne and Restylane Refyne, have been available in Canada, and Dr. Solish was involved in a Canadian study of the fillers in patients in motion. With the new fillers, “animation looks more natural after than before the fillers,” he said at the Hawaii Dermatology Seminar, provided by Global Academy for Medical Education/Skin Disease Education Foundation.
Patients attribute every nail problem to nail fungus, but part of the problem with nails is concomitant tinea pedis, tinea corporis, and other reservoirs of infection, according to Neal Bhatia, MD, director of clinical dermatology at Therapeutics Clinical Research in San Diego. Failure to locate and treat these other reservoirs can lead to recurrence of the nail infection, Dr. Bhatia said at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation.
The Food and Drug Administration approval of oxymetazoline 1% cream for the background erythema of rosacea is big news for dermatologists and patients, according to Linda Stein Gold, MD, director of dermatology research, Henry Ford Health System, Detroit.In studies, patients showed a two grade improvement in baseline erythema, and erythema reduction that lasted for 9-12 hours in many patients, said Dr. Stein Gold in a video interview, who was involved in the clinical trials.
Statins lowered all-cause mortality by 32% in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in a retrospective cohort study.The magnitude of benefit from statins in these two disease states is greater than that found in the general population (estimated 9%-14% reduction in all-cause mortality) and than that reported in patients with rheumatoid arthritis (RA, 21% reduction), said Amar Oza, MD, a second-year rheumatology fellow at Massachusetts General Hospital and Harvard Medical School, both in Boston.